Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from SAB Biotherapeutics (SABS).
SAB Biotherapeutics has successfully completed the third cohort dosing in phase one trials for their new drug, SAB-142, without any cases of serum sickness reported. The company plans to release a detailed corporate update mid-April, which could be a significant point of interest for investors and followers of the biotech industry.
For an in-depth examination of SABS stock, go to TipRanks’ Stock Analysis page.